Adverse events following immunization: real causality and myths

References

• Plotkin SA, Plotkin SL. A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia, PA: WB Saunders; 2012. p. 1–13.
   Google Scholar
• Minor PD. Polio vaccines and the eradication of poliomyelitis. Lancet. 2012;380:454–455.
   PubMed Web of Science ®Google Scholar
• Hajj Hussein I, Chams N, Chams S, et al. Vaccines through centuries: major cornerstones of global health. Front Public Health. 2015;3:269.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Adverse effects of vaccines: evidence and causality. Washington, DC: The National Academy Press; 2012.
   Google Scholar
• Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014;32:3725–3731.
   PubMed Web of Science ®Google Scholar
• Esposito S, Cecinati V, Brescia L, et al. Vaccinations in children with cancer. Vaccine. 2014;32:3725–3731.
   PubMed Web of Science ®Google Scholar
• Maglione MA, Das L, Raaen L, et al. Safety of vaccines used for routine immunization of U.S. children: a systematic review. Pediatrics. 2014;134:325–337.
   PubMed Web of Science ®Google Scholar
• Piccirilli G, Lazzarotto T, Chiereghin A, et al. Spotlight on measles in Italy: why outbreaks of a vaccine-preventable infection continue in the 21st century. Expert Rev Anti Infect Ther. 2015;13:355–362.
   PubMed Web of Science ®Google Scholar
• Vaccinee Europe. An industry for healthy lives. How are vaccines produced?; [ cited 2015 Dec 7]. Available from: http://www.vaccineseurope.eu/about-vaccines/key-facts-on-vaccines/how-are-vaccines-produced/
   Google Scholar
• Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations. An epidemiological review. Paediatr Drugs. 2000;2:273–290.
   PubMedGoogle Scholar
• Lopalco PL, DeStefano F. The complementary role of phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine. 2015;33:1541–1548.
   PubMed Web of Science ®Google Scholar
• Lindquist M. Use of triage strategies in the WHO signal-detection process. Drug Saf. 2007;30:635–637.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Nguyen M, Martin D, et al. Safe monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33:4398–4405.
   PubMed Web of Science ®Google Scholar
• Santuccio C, Trotta F, Felicetti P. Ongoing pharmacovigilance on vaccines. Pharmacol Res. 2015;92:2–5.
   PubMed Web of Science ®Google Scholar
• Crawford NW, Clothier H, Hodgson K, et al. Active surveillance for adverse events following immunization. Expert Rev Vaccines. 2014;13:265–276.
   PubMed Web of Science ®Google Scholar
• Baggs J, Gee J, Lewis E, et al. The vaccine safety datalink: a model for monitoring immunization safety. Pediatrics. 2011;127(Suppl. 1):S45–S53.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD); [ cited 2015 Dec 2]. Available from: http://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html
   Google Scholar
• European Medicines Agency. Pharmacovigilance. [ cited 2015 Dec 6]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000258.jsp&mid=WC0b01ac05800241de
   Google Scholar
• VAESCO. Vaccine Adverse Event Surveillance & Communication; [ cited 2015 Dec 2]. Available from: https://brightoncollaboration.org/vaesco.html
   Google Scholar
• Hallas J, Pottegård A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med. 2014;275:581–589.
   PubMed Web of Science ®Google Scholar
• Weldeselassie YG, Whitaker HJ, Farrington CP. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect. 2011;139:1805–1817.
   PubMed Web of Science ®Google Scholar
• McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2015 Sep 28. Epub. pii: S0091-6749(15)01160-4. doi:10.1016/j.jaci.2015.07.048.
   PubMed Web of Science ®Google Scholar
• Ruggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5675–5684.
   PubMed Web of Science ®Google Scholar
• Rutkowski K, Ewan PW, Nasser SM. Administration of yellow fever vaccine in patients with egg allergy. Int Arch Allergy Immunol. 2013;161:274–278.
   PubMed Web of Science ®Google Scholar
• Des Roches A, Paradis L, Gagnon R, et al. Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol. 2012;130:1213–1216.
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol. 1996;98:1058–1061.
   PubMed Web of Science ®Google Scholar
• Chung EH. Vaccine allergies. Clin Exp Vaccine Res. 2014;3:50–57.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Latex in vaccine packaging; [ cited 2013 Dec 3]. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/latex-table.pdf
   Google Scholar
• Chaves SS, Haber P, Walton K, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. J Infec Dis. 2008;197(Suppl. 2):S170–S177.
   PubMed Web of Science ®Google Scholar
• Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis. 2008;197(Suppl. 2):S165–S169.
   PubMed Web of Science ®Google Scholar
• Kramer JM, LaRussa P, Tsai WC, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics. 2001;108:e39.
   Google Scholar
• Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2001;19:916–923.
   Web of Science ®Google Scholar
• Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. Jama. 2000;284:1271–1279.
   PubMed Web of Science ®Google Scholar
• Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis. 1999;29:855–861.
   PubMed Web of Science ®Google Scholar
• Baram TZ, Gonzalez-Gomez I, Xie ZD, et al. Subacute sclerosing panencephalitis in an infant: diagnostic role of viral genome analysis. Ann Neurol. 1994;36:103–108.
   PubMed Web of Science ®Google Scholar
• Poon TP, Tchertkoff V, Win H. Subacute measles encephalitis with AIDS diagnosed by fine needle aspiration biopsy - a case report. Acta Cytol. 1998;42:729–733.
   PubMedGoogle Scholar
• Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345:567–569.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Ray WA, Mortimer EA, et al. Risk of seizures after measles-mumps-rubella immunization. Pediatrics. 1991;88:881–885.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews N, Stowe J, et al. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol. 2007;165:704–709.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Adverse events following immunization. Atlanta, G: US Department of Health and Human Services, Public Health Service, CDC; 1989. Surveillance Report no. 3, 1985–1986.
   Google Scholar
• Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the vaccine safety datalink project. The vaccine safety datalink team. Pediatrics. 1997;100:767–771.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 1998;47(No.RR–8):38–39.
   Google Scholar
• Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27:4656–4661.
   PubMed Web of Science ®Google Scholar
• Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126:e1–e8.
   PubMed Web of Science ®Google Scholar
• Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR–3):1–12.
   PubMedGoogle Scholar
• Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol. 2003;55:107–111.
   PubMed Web of Science ®Google Scholar
• France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008;121:e687–e692.
   PubMed Web of Science ®Google Scholar
• Jonville-Béra AP, Autret E, Galy-Eyraud C, et al. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. Pediatr Infect Dis J. 1996;15:44–48.
   PubMed Web of Science ®Google Scholar
• Kiefaber RW. Thrombocytopenic purpura after measles vaccination. N Engl J Med. 1981;305:225.
   PubMed Web of Science ®Google Scholar
• Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr. 2010;156:623–628.
   PubMed Web of Science ®Google Scholar
• Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84:227–229.
   PubMed Web of Science ®Google Scholar
• Okazaki N, Takeguchi M, Sonoda K, et al. Detection of platelet-binding anti-measles and anti-rubella virus IgG antibodies in infants with vaccine-induced thrombocytopenic purpura. Vaccine. 2011;29:4878–4880.
   PubMed Web of Science ®Google Scholar
• Nieminen U, Peltola H, Syrjälä MT, et al. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr. 1993;82:267–270.
   PubMed Web of Science ®Google Scholar
• Jonville-Béra AP, Autret E, Galy-Eyraud C, et al. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. Pediatr Infect Dis J. 1996;15:44–48.
   PubMed Web of Science ®Google Scholar
• Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J. 1996;15:88–90.
   PubMed Web of Science ®Google Scholar
• De Menezes Martins R, Fernandes Leal Mda L, Homma A. Serious adverse events associated with yellow fever vaccine. Hum Vaccin Immunother. 2015;11:2183–2187.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Yellow fever vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2010;59(RR–7):1–27.
   Google Scholar
• Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32:5769–5775.
   PubMed Web of Science ®Google Scholar
• McMahon AW, Eidex RB, Marfin AA, et al., et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine. 2007;25:1727–1734.
   PubMed Web of Science ®Google Scholar
• Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert Rev Vaccines. 2013;12:1351–1368.
   PubMed Web of Science ®Google Scholar
• Martins Rde M, Pavão AL, De Oliveira PM, et al., et al Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil. Vaccine. 2014;32:6676–6682.
   PubMed Web of Science ®Google Scholar
• Naleway AL, Gold R, Drew L, et al. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health (Larchmt). 2012;21:425–432.
   PubMed Web of Science ®Google Scholar
• Kroger AT, Sumaya CV, Pickering LK, et al. General recommendations on immunization: recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2011;60(RR02):1–60.
   Google Scholar
• Atanasoff S, Ryan T, Lightfoot R, et al. Shoulder injury related to vaccine administration (SIRVA). Vaccine. 2010;28:8049–8052.
   PubMed Web of Science ®Google Scholar
• Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. Bmj. 1992;304:1075–1078.
   PubMed Web of Science ®Google Scholar
• Dos Santos BA, Ranieri TS, Bercini M, et al. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Rev Panam Salud Publica. 2002;12:240–246.
   PubMedGoogle Scholar
• Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:1384–1387.
   PubMed Web of Science ®Google Scholar
• De Serres G, Grenier JL, Toth E, et al. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine. 2003;21:2354–2361.
   PubMed Web of Science ®Google Scholar
• Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the vaccine safety datalink project 2010–2011. Vaccine. 2012;30:2014–2031.
   Web of Science ®Google Scholar
• Velázquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J. 2012;31:736–744.
   PubMed Web of Science ®Google Scholar
• Patel MM, López-Collada VR, Bulhões MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364:2283–2292.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccine safety. Update on intussusception following rotavirus vaccine administration; [ cited 2016 Feb 3]. Available from: http://www.who.int/vaccine_safety/committee/topics/rotavirus/rotarix_and_rotateq/dec_2013/en/
   Google Scholar
• Martín Arias LH, Sanz R, Sáinz M, et al. Guillain–Barré syndrome and influenza vaccines: a meta-analysis. Vaccine. 2015;33:3773–3778.
   PubMed Web of Science ®Google Scholar
• Blum S, McCombe PA. Genetics of Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst. 2014;19:88–103.
   PubMed Web of Science ®Google Scholar
• Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637–641.
   PubMed Web of Science ®Google Scholar
• Hodgson H. A statement by The Royal Free and University College Medical School and The Royal Free Hampstead NHS Trust. Lancet. 2004;363:824.
   PubMed Web of Science ®Google Scholar
• Sotir MJ, Esposito DH, Barnett ED, et al. Measles in the 21st century, a continuing preventable risk to travelers: data from the GeoSentinel Global Network. Clin Infect Dis. 2016;62:210–212.
   PubMed Web of Science ®Google Scholar
• Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347:1477–1482.
   PubMed Web of Science ®Google Scholar
• Uchiyama T, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. J Autism Dev Disord. 2007;37:210–217.
   PubMed Web of Science ®Google Scholar
• Andrews N, Miller E, Grant A, et al. Thimerosal expo-sure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics. 2004;114:584–591.
   PubMed Web of Science ®Google Scholar
• Verstraeten T, Davis RL, De Stefano F, et al. Safety of thimerosal-containing vac-cines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003;112:1039–1048.
   PubMed Web of Science ®Google Scholar
• Hviid A, Stellfeld M, Wohlfahrt J, et al. Association between thimerosal-containing vaccine and autism. Jama. 2003;290:1763–1766.
   PubMed Web of Science ®Google Scholar
• DeStefano F, Bhasin TK, Thompson WW, et al. Age at first measles–mumps–rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics. 2004;113:259–266.
   PubMed Web of Science ®Google Scholar
• Mrozek-Budzyn D, Kiełtyka A, Majewska R. Lack of association between measles–mumps–rubella vaccination and autism in children: a case-controlstudy. Pediatr Infect Dis J. 2010;29:397–400.
   PubMed Web of Science ®Google Scholar
• Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet. 2004;364:963–969.
   PubMed Web of Science ®Google Scholar
• Uno Y, Uchiyama T, Kurosawa M, et al. The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine. 2012;30:4292–4298.
   PubMed Web of Science ®Google Scholar
• Price CS, Thompson WW, Goodson B, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics. 2010;126:656–664.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Vaccine Safety, MMR and autism; [ cited 2015 Dec 2]. Available from: http://www.who.int/vaccine_safety/committee/topics/mmr/Dec_2002/en/
   Google Scholar
• Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32:3623–3629.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep. 1999;48:563–565.
   PubMedGoogle Scholar
• Pichichero ME, Cernichiari E, Lopreiato J, et al. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet. 2002;360:1737–1741.
   PubMed Web of Science ®Google Scholar
• Axton JHM. Six cases of poisoning after a parenteral organic mercurial compound (merthiolate). Postgrad Med J. 1972;48:417–421.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics (AAP), Committee on Infectious Disease, Committee on Environmental Health. Thimerosal in vaccines – an interim report to clinicians. Pediatrics. 1999;104:570–574.
   PubMed Web of Science ®Google Scholar
• Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003;112:1039–1048.
   PubMed Web of Science ®Google Scholar
• Stehr-Green P, Tull P, Stellfeld M, et al. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med. 2003;25:101–106.
   PubMed Web of Science ®Google Scholar
• Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis. 2009;48:456–461.
   PubMed Web of Science ®Google Scholar
• Heron J, Golding J. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association. Pediatrics. 2004;114:577–583.
   PubMed Web of Science ®Google Scholar
• Price CS, Thompson WW, Goodson B, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics. 2010;126:656–664.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007;357:1281–1292.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global vaccine safety. Thiomersal and vaccines: questions and answers; [ cited 2015 Dec 2]. Available from: http://www.who.int/vaccine_safety/committee/topics/thiomersal/questions/en/
   Google Scholar
• Food and Drug Administration. Thimerosal in vaccines; [ cited 2015 Dec 2]. Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228#saf
   Google Scholar
• The European Agency for the Evaluation of Medicinal Products. EMEA public statement on thiomersal in vaccines for human use. Recent evidences support safety of thiomersal-containing vaccines; [ cited 2015 Dec 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003904.pdf
   Google Scholar
• DIAMOND Project G. Incidence and trends of childhood type 1 diabetes worldwide 1990–1999. Diabet Med. 2006;23:857–866.
   PubMed Web of Science ®Google Scholar
• Kaila B, Taback SP. The effect of day care exposure on the risk of developing type 1 diabetes: a meta-analysis of case–control studies. Diabetes Care. 2001;24:1353–1358.
   PubMed Web of Science ®Google Scholar
• Morgan E, Halliday SR, Campbell GR, et al. Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia. 2016;59:237–243.
   Google Scholar
• Stowe J, Andrews N, Wise L, et al. Investigation of the temporal association of Guillain–Barré syndrome with influenza vaccine and influenza-like illness using the United Kingdom general practice research database. Am J Epidemiol. 2009;169:382–388.
   PubMed Web of Science ®Google Scholar
• Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project. Am J Epidemiol. 2010;171:177–188.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13–17 years-United States 2012. Mmwr. 2013;2:685–693.
   Google Scholar
• Hughes A, Mesher D, White J, et al. Coverage of the English national human papillomavirus (HPV) immunisation programme among 12 to 17 year-old females by area-level deprivation score, England, 2008 to 2011. Euro Surveill. 2014;19. pii20677
   Google Scholar
• Tomljenovic L, Spinosa JP, Shaw CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des. 2013;19:1466–1487.
   PubMed Web of Science ®Google Scholar
• Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. Bmj. 2013;347:f5906.
   PubMed Web of Science ®Google Scholar
• Macartney KK, Chiu C, Georgousakis M, et al. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013;36:393–412.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:3000–3004.
   Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs. 2014;74:1253–1283.
   PubMed Web of Science ®Google Scholar
• Scheller NM, Pasternak B, Svanström H, et al. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. Jama. 2014;312:187–188.
   PubMed Web of Science ®Google Scholar
• Scheller NM, Svanström H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. Jama. 2015;313:54–61.
   PubMed Web of Science ®Google Scholar
• Choong K. Hypotonic IV fluid administration is associated with hyponatremia. J Pediatr. 2014;164:1239–1240.
   PubMed Web of Science ®Google Scholar
• Vichnin M, Bonanni P, Klein NP, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34:983–991.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global vaccine safety. Human papillomavirus (HPV) vaccine safety; [ cited 2015 Dec 7] Available from: http://www.who.int/vaccine_safety/committee/topics/hpv/dec_2013/en/
   Google Scholar
• Centers for Disease Control and Prevention. Human papillomavirus (HPV). HPV safety; [ cited 2015 Dec 7]. Available from: http://www.cdc.gov/hpv/parents/vaccinesafety.html
   Google Scholar
• European Medicines Agency. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS; [ cited 2015 Dec 7]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Human_papillomavirus_vaccines/human_referral_prac_000053.jsp&mid=WC0b01ac05805c516f
   Google Scholar
• Uppsala Monitoring Center. VigiBase; [ cited 2016 Mar 10]. Available from: http://www.umc-products.com/DynPage.aspx?id=73590&mn1=1107&mn2=1132
   Google Scholar